Pfizer’s sweetened $106 bn offer for AstraZeneca rejected
US pharma major Pfizer’s third attempt to acquire AstraZeneca with a sweetened offer of USD 106 billion was rejected on Friday.
This is the third time that AstraZeneca has rejected Pfizer’s offer and the second in less than a week. Pfizer, the New York-headquartered maker of cholesterol drug Lipitor and Viagra, had made an offer of USD 100 billion earlier.
“Pfizer today announces that, having consulted with major shareholders, it has submitted a revised written proposal to AstraZeneca plc to make an offer to combine the two companies,” the company said in a statement.